News | Heart Valve Technology | March 03, 2017

U.K. Patent Court Rules in Edwards Lifesciences TAVR Case Against Boston Scientific

Lotus Edge Valve, boston scientific, TAVR, TAVI, patent, patent lawsuit

The Boston Scientific Lotus TAVR valve.

March 3, 2017 — In a United Kingdom patent case involving a Edwards Lifesciences lawsuit against Boston Scientific for what the company said are invalid patents related to transcatheter valve seals, the court today ruled one of Boston's patents invalid, while a second patent is valid. Edwards said in a statement it will promptly request an appeal on specific aspects of the decision. 

The patent case is over the outer seals for Boston’s transcatheter Lotus heart valve and Edwards’ Sapien 3 valve. The seals are used to prevent paravalvular leak. 

Boston Scientific initiated litigation that now involves multiple patents in multiple venues, and will likely yield court actions over an extended period of time. Edwards said it is not changing its financial guidance and the court decision does not affect commercial availability of the Sapien 3 valve. 

In November 2015, Boston Scientific filed suit against Edwards in Germany based on European patents related to outer seals of transcatheter heart valves. In response, Edwards countersued, alleging infringement by the Lotus valve of foundational patents for this technology. Subsequently, suits were also filed in the U.K. Patents Court, which is what was decided today.  Edwards contends Boston Scientific obtained these patents long after Edwards completed many comprehensive clinical evaluations, advanced the therapy through multiple regulatory approval processes, supported the training of heart teams around the world with its Sapien 3 valve. 

Watch the VIDEO "The State of TAVR in 2016."
 

 

Related Content

News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...